Skip to Content

Takeda Pharmaceutical Co Ltd 4502

Morningstar Rating
JPY 4,028.00 +5.00 (0.12%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Takeda's Pipeline Has Promise but Is Still Developing

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management is undertaking an ambitious overhaul to diversify away from its stagnant local market and overcome patent expiries with acquisitions. In January 2019, it closed its purchase of Shire Plc for approximately $57 billion. The mega-deal not only gave Takeda access to Shire’s rare-disease and plasma-derived therapies, it also granted Takeda much greater penetration into United States' markets and diversification away from Japan’s cost-cutting policies.

Price vs Fair Value

4502 is trading at a 483% premium.
Price
JPY 4,028.00
Fair Value
JPY 3,937.00
Uncertainty
Medium
1-Star Price
JPY 3,546.00
5-Star Price
JPY 3,844.00
Economic Moat
Tqxpp
Capital Allocation
Jqmqvdc

Bulls Say, Bears Say

Bulls

Takeda has shown good progress on its cost-cutting initiatives and continues to focus on improving its operational efficiency.

Bears

Takeda’s pipeline is mostly early stage, and success or failure of clinical trials will be critical in determining the market’s perception of the company.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 4502 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
JPY 4,023.00
Day Range
JPY 4,022.004,070.00
52-Week Range
JPY 3,900.004,873.00
Bid/Ask
JPY 4,027.00 / JPY 4,035.00
Market Cap
JPY 6.32 Tril
Volume/Avg
6.3 Mil / 4.0 Mil

Key Statistics

Price/Earnings (Normalized)
15.26
Price/Sales
1.49
Dividend Yield (Trailing)
4.67%
Dividend Yield (Forward)
4.87%
Total Yield
4.70%

Company Profile

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Core
Total Number of Employees
49,095

Competitors

Valuation

Metric
4502
4519
4568
Price/Earnings (Normalized)
15.2627.1149.30
Price/Book Value
0.875.176.19
Price/Sales
1.498.196.53
Price/Cash Flow
7.3025.5339.92
Price/Earnings
4502
4519
4568

Financial Strength

Metric
4502
4519
4568
Quick Ratio
0.464.212.32
Current Ratio
1.065.533.01
Interest Coverage
1.9335.14
Quick Ratio
4502
4519
4568

Profitability

Metric
4502
4519
4568
Return on Assets (Normalized)
2.86%17.64%6.99%
Return on Equity (Normalized)
6.13%21.05%12.93%
Return on Invested Capital (Normalized)
4.78%20.98%10.69%
Return on Assets
4502
4519
4568
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
ScmtppjzkTgv$78.1 Bil
Merck KGaA ADR
MKKGY
WnxfdmbkxtMhkrty$77.8 Bil
Haleon PLC ADR
HLN
TfnchyxrCbgj$38.6 Bil
Viatris Inc
VTRS
TllsxlkrYyld$12.5 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
XfvbldhgMjzwy$12.0 Bil
Catalent Inc
CTLT
JllrsdctHkddxhm$10.2 Bil
Perrigo Co PLC
PRGO
JfktrmrkSswt$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
LphhhnrQvqfjc$3.5 Bil
Curaleaf Holdings Inc
CURLF
LmfvkcfbDvcn$3.0 Bil
Green Thumb Industries Inc
GTBIF
NcrshssfpCxqd$2.8 Bil

Sponsor Center